

**Discussion Agenda**

Memorandum and resolution re: Final Rule to Revise 12 CFR 360.10 and Associated Delegations of Authority.

Memorandum and resolution re: Board Briefings on Certain Merger and Deposit Insurance Applications Outstanding for More Than 270 Days.

**CONTACT PERSON FOR MORE INFORMATION:**

Direct requests for further information concerning the meeting to Debra A. Decker, Executive Secretary of the Corporation, at 202-898-8748.

*Authority:* 5 U.S.C. 552b.

Dated at Washington, DC, on June 20, 2024.  
Federal Deposit Insurance Corporation.

**James P. Sheesley,**

*Assistant Executive Secretary.*

[FR Doc. 2024-13950 Filed 6-25-24; 8:45 am]

**BILLING CODE 6714-01-P**

**FEDERAL RESERVE SYSTEM**

[Docket No. OP-1831]

**Expanded Hours for Fedwire Funds Service & National Settlement Service**

**AGENCY:** Board of Governors of the Federal Reserve System.

**ACTION:** Request for comment; extension of comment period.

**SUMMARY:** On May 9, 2024, the Board of Governors of the Federal Reserve System (Board) published in the **Federal Register** a proposal to expand the operating hours of the Fedwire® Funds Service and the National Settlement Service (NSS). The Board proposed to expand the operating hours of the Fedwire Funds Service to 22 hours per day, 7 days per week, every day of the year (22x7x365) and to correspondingly expand the operating hours of NSS, with NSS closing 30 minutes earlier than the Fedwire Funds Service. The proposal provided for a comment period ending on July 8, 2024. The Board is extending the comment period for 60 days, until September 6, 2024.

**DATES:** The notification published on May 9, 2024 (89 FR 39613), is extended. Comments must be received by September 6, 2024.

**ADDRESSES:** You may submit comments by any of the methods identified in the proposal.

**FOR FURTHER INFORMATION CONTACT:**

Mark Magro, Manager, Division of Reserve Bank Operations and Payment Systems (202-452-3944); Ann Sun, Lead Financial Institution Policy Analyst, Division of Reserve Bank Operations and Payment Systems (202-912-7938); Gavin Smith, Senior Counsel, Legal Division (202 452-3474);

or Corinne Milliken Van Ness, Senior Counsel, Legal Division (202-452-2421), Board of Governors of the Federal Reserve System. For users of TTY-TRS, please call 711 from any telephone, anywhere in the United States.

**SUPPLEMENTARY INFORMATION:** On May 9, 2024, the Board of Governors of the Federal Reserve System (Board) published a proposal to expand the operating hours of the Fedwire® Funds Service and the National Settlement Service (NSS) in the **Federal Register**. The Board proposed to expand the operating hours of the Fedwire Funds Service to 22 hours per day, 7 days per week, every day of the year (22x7x365) and to correspondingly expand the operating hours of the NSS, with the NSS closing 30 minutes earlier than the Fedwire Funds Service.<sup>1</sup>

The proposal provided for a comment period ending on July 8, 2024. The Board is extending the comment period for 60 days, until September 6, 2024. Since the publication of the proposal, the Board has received comments requesting an extension of the comment period. An extension of the comment period will provide additional opportunity for interested parties to analyze the proposal and prepare and submit comments. Therefore, the Board is extending the end of the comment period for the proposal from July 8, 2024, to September 6, 2024.

By order of the Board of Governors of the Federal Reserve System, acting through the Secretary of the Board under delegated authority.

**Ann E. Misback,**

*Secretary of the Board.*

[FR Doc. 2024-14018 Filed 6-25-24; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration**

[Docket No. FDA-2024-N-2886]

**Food and Drug Administration Information Technology Strategy and Customer Experience Strategy; Request for Comments**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; request for comment.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is requesting comments on its “Information Technology (IT) Strategy” and “Customer Experience (CX)

Strategy.” In accordance with the Agency’s User Fee Program commitments and Omnibus Bill requirements, FDA must annually update and publish its IT Strategy by September 30. The initial strategy, released in September 2023, outlines the future direction of FDA’s data and technology capabilities. A key objective of FDA’s IT Strategy is to modernize enterprise services and capabilities to improve customer experience. The FDA CX Strategy was created to guide this effort. This comprehensive enterprise plan introduces the Agency’s CX framework and considers the perspective of interested parties such as the public, employees, and industry.

**DATES:** Submit either electronic or written comments on the IT Strategy by July 31, 2024, to ensure that the Agency considers your comments for future iterations of the IT Strategy.

**ADDRESSES:** You may submit comments as follows:

*Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

*Written/Paper Submissions*

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management

<sup>1</sup> 89 FR 39613 (May 9, 2024).